Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Donald Trump is executing a shock-and-awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...

The FDA's move may change how doctors treat chronic kidney disease, which, according to Ozempic maker Novo Nordisk, affects around 37 million Americans and is one of the leading causes of death in the ...

Jim Cramer in a latest program on CNBC reminded viewers about the Trump playbook in the story market and said that he never ...

Shares in Novo Nordisk rose as much as 13 per cent on Friday ... Lilly’s diabetes drug Mounjaro and weight loss treatment Zepbound offer higher average weight loss than Wegovy.

USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license agreement with Novo Nordisk (NOV ... Receive The Pharma Letter daily news bulletin ...

Outgoing presidents traditionally leave a letter for the incoming president. Former President Joe Biden wished President Donald Trump "all the best for the next four years" in the letter he left ...

Few drugs have generated as much excitement as Novo Nordisk's (NYSE ... The agency will send its final offer on drug prices by Oct. 15, 2025. Drugmakers must accept or reject the final offer ...

WASHINGTON − Former President Joe Biden left a letter for the man replacing him in the Oval Office, continuing a tradition dating back 36 years. President Donald Trump discovered the letter, which was ...

The South African government increased its pay offer to public sector workers to 5.5% from 5%, as it seeks to end wage talks that began in September. The latest offer presented at a special council ...

Bernard Arnault is once again in charge of Europe's most valuable company. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

Novo Nordisk has commenced the STEP UP and STEP UP T2D trials to explore the efficacy of semaglutide 7.2mg. Credit: © 2025 Novo Nordisk A/S. Novo Nordisk’s high ...